Advertisement

In Vivo Microdialysis to Study Striatal Dopaminergic Neurodegeneration

  • Giuseppe Di Giovanni
  • Massimo Pierucci
  • Mauro Pessia
  • Vincenzo Di MatteoEmail author
Protocol
Part of the Neuromethods book series (NM, volume 75)

Abstract

Microdialysis cerebral technique has been widely employed in order to study neurotransmitter release. This technique presents numerous advantages such as it allows work with sample in vivo from freely moving animals. Different drugs in different points implanted probes in several brain areas can be infused simultaneously by means of microdialysis. Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopamine (DA) neurons in the nigrostriatal system, which in turn produces profound neurochemical changes within the basal ganglia, representing the neural substrate for Parkinsonian motor symptoms. Over the years, a broad variety of experimental models of the disease have been developed and applied in diverse animal species. The two most common toxin models used employ 6-hydroxydopamine (6-OHDA) and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/1-methyl-4-phenilpyridinium ion (MPTP/MPP+), either given systemically or locally applied into the nigrostriatal pathway, to resemble PD features in animals. Both neurotoxins selectively and rapidly destroy catecholaminergic neurons, although with different mechanisms. Since in vivo microdialysis coupled to high-performance liquid chromatography (HPLC) is an established technique for studying physiological, pharmacological, and pathological changes of a wide range of low molecular weight substances in the brain extracellular fluid, here we describe a rapid and simple microdialysis technique that allows the direct quantitative study of the damage produced by 6-OHDA and MPP+ toxins on dopaminergic (DAergic) striatal terminals of rat brain.

Key words

Parkinson’s disease In vivo microdialysis Corpus striatum MPP+ 6-OHDA ROS 

Notes

Acknowledgments

Authors are indebted to the EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” for supporting our international collaboration.

References

  1. 1.
    Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol 62:63–88PubMedCrossRefGoogle Scholar
  2. 2.
    Di Giovanni G (2008) Will it ever become possible to prevent dopaminergic neuronal degeneration? CNS Neurol Disord Drug Targets 7:28–44PubMedCrossRefGoogle Scholar
  3. 3.
    Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–224PubMedCrossRefGoogle Scholar
  4. 4.
    Beal MF (2001) Experimental models of Parkinson’s disease. Nat Rev Neurosci 2:325–334PubMedCrossRefGoogle Scholar
  5. 5.
    Ungerstedt U (1991) Microdialysis: principles and applications for studies in animals and man. J Intern Med 230:365–373PubMedCrossRefGoogle Scholar
  6. 6.
    Hammarlund-Udenaes M (2000) The use of microdialysis in CNS drug delivery studies: pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 45:283–294PubMedCrossRefGoogle Scholar
  7. 7.
    Di Giovanni G, Esposito E, Di Matteo V (2009) In vivo microdialysis in Parkinson’s research. J Neural Transm Suppl 73:223–243PubMedGoogle Scholar
  8. 8.
    Giovanni A, Sonsalla PK, Heikkila RE (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 2. Central administration of 1- methyl-4-phenylpyridinium. J Pharmacol Exp Ther 270:1008–1014PubMedGoogle Scholar
  9. 9.
    Rollema H, Kuhr WG, Kranenborg G, De Vries J, Van den Berg C (1988) MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J Pharmacol Exp Ther 245:858–866PubMedGoogle Scholar
  10. 10.
    Tobón-Velasco JC, Silva-Adaya D, Carmona-Aparicio L, García E, Galván-Arzate S, Santamaría A (2010) Early toxic effect of 6-hydroxydopamine on extracellular concentrations of neurotransmitters in the rat striatum: an in vivo microdialysis study. Neurotoxicology 31:715–723PubMedCrossRefGoogle Scholar
  11. 11.
    Benveniste H, Huttemeier PC (1990) Microdialysis: theory and application. Prog Neurobiol 35:195–215PubMedCrossRefGoogle Scholar
  12. 12.
    Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, New YorkGoogle Scholar
  13. 13.
    Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, Esposito E (2006) Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res 1095:167–177PubMedCrossRefGoogle Scholar
  14. 14.
    Di Matteo V, Benigno A, Pierucci M, Giuliano DA, Crescimanno G, Esposito E, Di Giovanni G (2006) 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann N Y Acad Sci 1089:462–471PubMedCrossRefGoogle Scholar
  15. 15.
    Chiueh CC, Krishna G, Tulsi P, Obata T, Lang K, Huang S-J, Murphy DL (1992) Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+. Free Radic Biol Med 13:581–583PubMedCrossRefGoogle Scholar
  16. 16.
    Teismann P, Schwaninger M, Weih F, Ferger B (2001) Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson’s disease. Neuroreport 12:1049–1053PubMedCrossRefGoogle Scholar
  17. 17.
    Obata T (2006) Nitric oxide and MPP+-induced hydroxyl radical generation. J Neural Transm 113:1131–1144PubMedCrossRefGoogle Scholar
  18. 18.
    Halliwell B, Kaur H, Ingelman-Sundberg M (1991) Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Radic Biol Med 10:439–441PubMedCrossRefGoogle Scholar
  19. 19.
    Halliwell B, Kaur H (1997) Hydroxylation of salicylate and phenylalanine as assays for hydroxyl radicals: a cautionary note visited for the third time. Free Radic Res 27:239–244PubMedCrossRefGoogle Scholar
  20. 20.
    Montgomery J, Ste-Marie L, Boismenu D, Vachon L (1995) Hydroxylation of aromatic compounds as indices of hydroxyl radical production: a cautionary note revisited. Free Radic Biol Med 19:927–933PubMedCrossRefGoogle Scholar
  21. 21.
    Ste-Marie L, Boismenu D, Vachon L, Montgomery J (1996) Evaluation of sodium 4-hydroxybenzoate as an hydroxyl radical trap using gas chromatography-mass spectrometry and high-performance liquid chromatography with electochemical detection. Anal Biochem 241:67–74PubMedCrossRefGoogle Scholar
  22. 22.
    Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, Abramson SB (1995) The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 92(17):7926–7930PubMedCrossRefGoogle Scholar
  23. 23.
    Liu M, Liu S, Peterson SL, Miyake M, Liu KJ (2002) On the application of 4-hydroxybenzoic acid as a trapping agent to study hydroxyl radical generation during cerebral ischemia and reperfusion. Mol Cell Biochem 234(235):379–385PubMedCrossRefGoogle Scholar
  24. 24.
    Bogdanov MB, Ferrante RJ, Mueller G, Ramos LE, Martinou JC, Beal MF (1999) Oxidative stress is attenuated in mice overexpressing BCL-2. Neurosci Lett 262:33–36PubMedCrossRefGoogle Scholar
  25. 25.
    Santiago M, Westerink BHC, Rollema H (199l) Responsiveness of striatal dopamine release in awake animals after chronic 1-methyl-4-phenylpyridinium ion-induced lesions of the substantia nigra. J Neurochem 56:1336–1134CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Giuseppe Di Giovanni
    • 1
  • Massimo Pierucci
    • 2
  • Mauro Pessia
    • 3
  • Vincenzo Di Matteo
    • 4
    Email author
  1. 1.Faculty of Medicine and Surgery, Department of Physiology and BiochemistryUniversity of MaltaMsida MSDMalta
  2. 2.Department of Physiology and BiochemistryUniversity of MaltaMsida MSDMalta
  3. 3.Section of Human PhysiologyUniversity of Perugia School of MedicinePerugiaItaly
  4. 4.Consorzio “Mario Negri” SudSanta Maria ImbaroChietiItaly

Personalised recommendations